Global Short-acting EPO Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Short-acting EPO Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
Global Short-acting EPO Drugs market is projected to reach US$ 13830 million in 2029, increasing from US$ 9180 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2029. Demand from Anemia and Kidney Disorders are the major drivers for the industry.
Short-acting EPO drugs have a wide range of applications in the market, primarily used for treating anemia-related conditions such as anemia associated with chronic kidney disease and in the supportive treatment of leukemia patients. The market size is substantial and continues to grow, particularly in Asian and European regions. Sales have been on the rise, reflecting increasing patient demand and benefiting from ongoing advancements in medical technology. In the future, short-acting EPO drugs are poised for further development, potentially encompassing the treatment of more anemia-related conditions and expanding their market share through innovative therapies and market expansion efforts.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Short-acting EPO Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Amgen
Johnson & Johnson
Roche
Kyowa Kirin
LG Chem
Daewoong Pharmaceutical
Wockhardt
CJ Healthcare
3SBio
Kexing Biopharm
Harbin Pharmaceutical Group
Beijing Four Rings Bio-Pharmaceutical
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Anemia
Kidney Disorders
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Short-acting EPO Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Short-acting EPO Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Short-acting EPO Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Short-acting EPO Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Short-acting EPO Drugs introduction, etc. Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Short-acting EPO Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Global Short-acting EPO Drugs market is projected to reach US$ 13830 million in 2029, increasing from US$ 9180 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2029. Demand from Anemia and Kidney Disorders are the major drivers for the industry.
Short-acting EPO drugs have a wide range of applications in the market, primarily used for treating anemia-related conditions such as anemia associated with chronic kidney disease and in the supportive treatment of leukemia patients. The market size is substantial and continues to grow, particularly in Asian and European regions. Sales have been on the rise, reflecting increasing patient demand and benefiting from ongoing advancements in medical technology. In the future, short-acting EPO drugs are poised for further development, potentially encompassing the treatment of more anemia-related conditions and expanding their market share through innovative therapies and market expansion efforts.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Short-acting EPO Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Amgen
Johnson & Johnson
Roche
Kyowa Kirin
LG Chem
Daewoong Pharmaceutical
Wockhardt
CJ Healthcare
3SBio
Kexing Biopharm
Harbin Pharmaceutical Group
Beijing Four Rings Bio-Pharmaceutical
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Segment by Application
Anemia
Kidney Disorders
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Short-acting EPO Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Short-acting EPO Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Short-acting EPO Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Short-acting EPO Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Short-acting EPO Drugs introduction, etc. Short-acting EPO Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Short-acting EPO Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.